RxDoctor Payments Data

Alana Starr, APRN

Family · Minden, NVNPI 1619642626

Payments from drug & device makers

$4,973in general payments, 2019–2025

Across 250 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$869
  • AstraZeneca$822
  • GSK$371
  • Pfizer$350
  • Lilly USA, LLC$182
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,973100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,973 in reported general payments places this provider in the 90th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$101,112
Medicare patients
330
Services billed
1,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$138,982
EliquisApixaban55$62,278
FarxigaDapagliflozin Propanediol42$62,033
JardianceEmpagliflozin47$56,245
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$44,157
XareltoRivaroxaban21$24,055
LinzessLinaclotide12$17,387
MounjaroTirzepatide14$14,423
PremarinEstrogens, Conjugated21$5,145
Rosuvastatin Calcium221$3,902
Atorvastatin Calcium244$3,237
Levothyroxine Sodium261$3,215
SymbicortBudesonide/Formoterol Fumarate13$2,912
SynthroidLevothyroxine Sodium41$2,802
Losartan Potassium230$2,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$869$138,98289 claims
PfizerEliquis, Premarin$350$67,42376 claims
AstraZenecaFarxiga, Symbicort$822$64,94555 claims
Boehringer IngelheimJardiance$181$56,24547 claims
GSKTrelegy Ellipta$371$44,15748 claims
AbbVieLinzess, Synthroid$1,270$20,18853 claims
Lilly USA, LLCMounjaro$182$14,42314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,501 family providers in Nevada.

Other family in Minden

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →